News & Views
Telix announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of…
Read more
Telix today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3…
Read more
Telix today announces thirteen abstract presentations featuring the Company’s ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37th Annual Congress of the European Association…
Read more
News,
Telix today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of 68Ga-PSMA-11[1] injection) to select patients for PSMA[2]-targeted radionuclide…
Read more
News,
Telix today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA[1]-targeted radionuclide…
Read more
Telix today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix’s first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentuximab) in recurrent clear…
Read more
Prostate Cancer Awareness Month,
During Prostate Cancer Awareness, Telix is speaking with the physicians, advocates and patients on the front line of fighting prostate cancer. Our third interview in the series is with Mike…
Read more
Telix and RLS (USA) Inc., America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent…
Read more
News,
Telix today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET agent, Zircaix® (TLX250-CDx)…
Read more
Prostate Cancer Awareness Month,
During Prostate Cancer Awareness, Telix is speaking with the physicians, advocates and patients on the frontlines of fighting prostate…
Read more